U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06853015) titled 'Double Dose 4-AP on Functional Recovery After Spinal Cord Injury' on Feb. 14.
Brief Summary: The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
SCI - Spinal Cord Injury
Intervention:
DRUG: Dalfampridine
The study drug (4-AP) will be administered as a 10 mg dose twice a day...